Final analysis from an open-label extension study of fenfluramine for the treatment of seizures in Lennox-Gastaut syndrome: long-term impact on patients and caregivers
Epilepsy & Behavior · 2025
DOI: 10.1016/j.yebeh.2025.110753 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Epilepsy & Behavior, 2025. Verfasst von Kelly G Knupp und 20 weiteren Autor:innen. Beteiligte Einrichtung: University of Colorado Anschutz Medical Campus, Aurora, CO, USA. Electronic address: Kelly.knupp@childrenscolorado.org. Hauptthemen laut MEDLINE: Lennox Gastaut Syndrome, Fenfluramine, Seizures, Caregivers. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UCB.
Abstract (Originalsprache)
OBJECTIVE: To describe long-term safety and effectiveness of fenfluramine in pediatric and adult patients with Lennox-Gastaut syndrome (LGS) from the final analysis of an open-label extension (OLE) study. METHODS: Patients (aged 2-35y) who participated in the randomized controlled trial (RCT) were eligible to continue in this OLE (NCT03355209). Fenfluramine 0.2 mg/kg/day was initiated; after one month, titration up to 0.7 mg/kg/day (26 mg/day maximum) was allowed. Key endpoints: incidence of treatment-emergent adverse events (TEAEs), median percentage change from RCT baseline in frequency of seizures associated with a fall, improvement by caregivers and investigators on Clinical Global Impression-Improvement (CGI-I), change from baseline in Quality of Life in Childhood Epilepsy Questionnaire scores, and Hospital Anxiety and Depression Scale (HADS) in parents/caregivers. RESULTS: 247 patients enrolled: 158 (64.0 %) patients completed this OLE. Mean ± SD age, 14.3 ± 7.6y; median fenfluramine exposure, 364d (range, 19-537); mean ± SD fenfluramine daily dose, 0.4 ± 0.1 mg/kg/day. TEAEs in ≥10 % of patients: decreased appetite, fatigue, nasopharyngitis, seizure, pyrexia; no valvular heart disease or pulmonary arterial hypertension cases. Median change in frequency of seizures associated with a fall from Month 2 to end of study: -31.1 % (n = 240; P < 0.0001); pediatric: -27.6 % (n = 170; P = 0.0005), adult: -40.0 % (n = 70; P < 0.0001). On last-visit CGI-I, caregivers and investigators rated 59.9 % and 57.0 % of patients as improved, respectively. At Month 12, mean overall patient quality of life and caregiver anxiety on HADS significantly improved from baseline. SIGNIFICANCE: These results support the long-term safety and effectiveness of fenfluramine in patients with LGS, with no new safety signals identified, and sustained reductions in seizures and improvement in global functioning observed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Colorado Anschutz Medical Campus, Aurora, CO, USA. Electronic address: Kelly.knupp@childrenscolorado.org.
- University of Melbourne, Austin Health, Heidelberg, Melbourne, Victoria, Australia; The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia; University of Melbourn…
- University Hospital Antwerp, Antwerp, Belgium. Electronic address: an-sofie.schoonjans@uza.be.
- Weill Institute for Neurosciences and Benioff Children's Hospital, University of California San Francisco, San Francisco, CA, USA. Electronic address: joseph.sullivan@UCSF.edu.
- University of Leuven, Leuven, Belgium; Leuven Childhood Epilepsy Center, Leuven Brain Institute, UZ Leuven, Member of the European Reference Network (ERN) EpiCARE, Leuven, Belgium. Electronic address: lieven.lagae@uzleu…
- AP-HP, Reference Center for Rare Epilepsies, Member of the ERN EpiCARE, Hôpital Universitaire Robert Debré, Paris, France; Institut Hospitalo-Universitaire Robert-Debré du Cerveau de l'Enfant, Paris, France; Université…
Förderung
- UCB
Zitieren
APA
Knupp, K. G., Scheffer, I. E., Schoonjans, A. S., Sullivan, J., Lagae, L., Auvin, S., Thiele, E. A., Guerrini, R., Zuberi, S. M., Nabbout, R., Riney, K., Nickels, K. C., Davis, R., Lock, M. D., Dai, D., Minh, T., Zhang Roper, R., Dickson, N., Langlois, M., …, & Gil-Nagel, A. (2025). Final analysis from an open-label extension study of fenfluramine for the treatment of seizures in Lennox-Gastaut syndrome: long-term impact on patients and caregivers. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2025.110753
Vancouver
Knupp KG, Scheffer IE, Schoonjans AS, Sullivan J, Lagae L, Auvin S, et al. Final analysis from an open-label extension study of fenfluramine for the treatment of seizures in Lennox-Gastaut syndrome: long-term impact on patients and caregivers. Epilepsy & Behavior. 2025. doi:10.1016/j.yebeh.2025.110753
BibTeX
@article{Knupp2025,
author = {Knupp, Kelly G and Scheffer, Ingrid E and Schoonjans, An-Sofie and Sullivan, Joseph and Lagae, Lieven and Auvin, Stéphane and Thiele, Elizabeth A and Guerrini, Renzo and Zuberi, Sameer M and Nabbout, Rima and Riney, Kate and Nickels, Katherine C and Davis, Ronald and Lock, Michael D and Dai, David and Minh, Timothy and Zhang Roper, Rebecca and Dickson, Najla and Langlois, Mélanie and Lothe, Amélie and Gil-Nagel, Antonio},
title = {Final analysis from an open-label extension study of fenfluramine for the treatment of seizures in Lennox-Gastaut syndrome: long-term impact on patients and caregivers},
journal = {Epilepsy & Behavior},
year = {2025},
doi = {10.1016/j.yebeh.2025.110753}
}
EUVIMED